A prospective, single-centre, observational, real world, post-marketing surveillance to evaluate safety and performance of the BioMimeâ?¢ Morph Sirolimus Eluting Coronary Stent System for very long coronary lesions

Meril Life Sciences Pvt Ltd0 个研究点目标入组 257 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.The patient must be at least 18 years of age. 2.Significant native coronary artery stenosis (more than 50% by visual estimate) with lesion length of less and equal to 56 mm.
•3.The patient or guardian agrees to the protocol requirements and the schedule of follow-up and provides informed written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.

•1. Patients who are actively participating in another drug or device investigational study.
•2.Patients who are unwilling to participate in the study.
•3.Patients contraindicated to any of the following medications aspirin, heparin, clopidogrel, cobalt chromium contrast agents and sirolimus.
•4.Female patient with known pregnancy or who are lactating.

发起方

Meril Life Sciences Pvt Ltd